"Design defect" suit threatens FDA review process

03/17/2013 | Politico (Washington, D.C.)

The "design defect" theory behind a lawsuit against generic-drug-maker Mutual Pharmaceutical could result in a wave of lawsuits second-guessing the approval of any drug, former FDA Deputy Commissioner Dr. Scott Gottlieb writes. "The theory would allow state juries to relitigate the risk-benefit analysis that is at the very core of the FDA's authority to approve prescription drugs," he writes.

View Full Article in:

Politico (Washington, D.C.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA